NCT06989918View on ClinicalTrials.gov

MHB018A Treatment in Patients With Active Thyroid Eye Disease

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

July 31, 2028

Conditions
Thyroid Associated Ophthalmopathies
Interventions
DRUG

MHB018A

MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)

DRUG

MHB018A placebo

6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)

Sponsors
All Listed Sponsors
lead

Minghui Pharmaceutical (Hangzhou) Ltd

INDUSTRY